Therapy of autoinflammatory syndromes
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
The therapy of autoinflammatory syndromes is an excellent example of the power of translational research. Recent advances in our understanding of the molecular and immunologic basis of this newly identified classification of disease have allowed for the application of novel, effective, targeted treatments with life-changing effects on patients. Although colchicine and TNF-α inhibitors are important therapies for specific autoinflammatory syndromes, the novel IL-1–targeted drugs are particularly effective for many of these diseases. Recently, the pharmaceutical industry has adopted a strategy of confirming the efficacy of new targeted drugs in often-ignored patients with orphan diseases, and US Food and Drug Administration policies have allowed for accelerated approval of these drugs, creating a win-win situation for patients and industry. This article reviews the general approach to the therapy of autoinflammatory diseases, focusing on current approved therapies and novel approaches that might be used in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryopyrin activates the inflammasome in response to toxins and ATP
Mariathasan, S., Weiss, D. S., Newton, K., McBride, J., O'Rourke, K., Roose-Girma, M., Lee, W. P., Weinrauch, Y., Monack, D. M., & Dixit, V. M. (2006) · Nature · doi:10.1038/nature04515 · Cited by 3,080
Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
Dostert, C., Pétrilli, V., Van Bruggen, R., Steele, C., Mossman, B. T., & Tschopp, J. (2008) · Science · doi:10.1126/science.1156995 · Cited by 2,658
The Inflammasomes: Guardians of the Body
Martinon, F., Mayor, A., & Tschopp, J. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132715 · Cited by 2,436 · cited 1×
“Once cryopyrin is activated, oligomerization of these protein components occurs through several specific protein-protein interaction domains to form a multimeric complex, which binds to and activates caspase 1, allowing for the cleavage of pro–IL-1b (Fig 2).(82) The mechanisms involved in the subsequent cellular relea…”
BackgroundAgostini, L., Martinon, F., Burns, K., McDermott, M. F., Hawkins, P. N., & Tschopp, J. (2004) · Immunity · doi:10.1016/s1074-7613(04)00046-9 · Cited by 1,768 · cited 4×
“However, some of the most dramatic therapeutic responses to anakinra were observed in patients with NOMID, the most severe form of CAPS.99 Since these initial reports, similar responses to anakinra have been observed in patients with CAPS to anakinra therapy with a variety of doses and treatment regimens.”
InfluentialActivation of the NALP3 inflammasome is triggered by low intracellular potassium concentration
Pétrilli, V, Papin, S., Dostert, C., Mayor, A., Martinon, F., & Tschopp, J. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402195 · Cited by 1,445
The Nalp3 inflammasome is essential for the development of silicosis
Cassel, S. L., Eisenbarth, S. C., Iyer, S. S., Sadler, J. J., Colegio, O. R., Tephly, L. A., Carter, A. B., Rothman, P. B., Flavell, R. A., & Sutterwala, F. S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803933105 · Cited by 907
Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome
Lachmann, H. J., Kone-Paut, I., Kuemmerle-Deschner, J. B., Leslie, K. S., Hachulla, E., Quartier, P., Gitton, X., Widmer, A., Patel, N., & Hawkins, P. N. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810787 · Cited by 869 · cited 5×
“In the one NOMID case in which anakinra was reported to be ineffective, dosing was not increased to greater than 1.6 mg/kg/d.101 In addition to improvement in daily symptoms and systemic markers of inflammation, some patients have also experienced resolution or significant improvement in long-term complications, such…”
InfluentialA pilot study of IL-1 inhibition by anakinra in acute gout
So, A., De Smedt, T., Revaz, S., & Tschopp, J. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2143 · Cited by 727
Hoffman, H. M., Throne, M. L., Amar, N. J., Sebai, M., Kivitz, A. J., Kavanaugh, A., Weinstein, S. P., Belomestnov, P., Yancopoulos, G. D., Stahl, N., et al. (2008) · Arthritis & Rheumatism · doi:10.1002/art.23687 · Cited by 577
Self-citationInflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity
Brydges, S. D., Mueller, J. L., McGeough, M. D., Pena, C. A., Misaghi, A., Gandhi, C., Putnam, C. D., Boyle, D. L., Firestein, G. S., Horner, A. A., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.005 · Cited by 339
Self-citation
Cited by
Phenotypical and functional specialization of FOXP3+ regulatory T cells
Campbell, D. J., & Koch, M. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri2916 · Cited by 773
Gerfaud-Valentin, M., Jamilloux, Y., Iwaz, J., & Sève, P. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.01.058 · Cited by 518
The NLRP3 inflammasome: Mechanism of action, role in disease and therapies
Wang, L., & Hauenstein, A. V. (2020) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2020.100889 · Cited by 426
The NLRP3 inflammasome in health and disease: the good, the bad and the ugly
Menu, P., & Vince, J. E. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04440.x · Cited by 389
Kebaier, C., Chamberland, R. R., Allen, I. C., Gao, X., Broglie, P. M., Hall, J. D., Jania, C., Doerschuk, C. M., Tilley, S. L., & Duncan, J. A. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jir846 · Cited by 257
Metadata
- Authors
- Hoffman, H. M.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2009-12
- Volume
- 124
- Issue
- 6
- Pages
- 1129-1138
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W2050781159
- Cited by
- 92
- References
- 10
- FWCI
- 3.84
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapy of autoinflammatory syndromes. https://app.cochat.ai/papers/10.1016/j.jaci.2009.11.001
- The paper
- Hoffman, H. M. (2009). Therapy of autoinflammatory syndromes. Journal of Allergy and Clinical Immunology. https://doi.org/10.1016/j.jaci.2009.11.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.